HomeMy WebLinkAbout08.01.22 Board Correspondence - FW_ Public health emergency of international concern (PHEIC) FAKE (2)
From:Clerk of the Board
To:Pickett, Andy; Valencia, Shyanne; Reaster, Kayla
Subject:Board Correspondence - FW: Public health emergency of international concern (PHEIC) FAKE
Date:Monday, August 1, 2022 2:18:04 PM
Shaina Paulsen
Associate Clerk of The Board
Butte County Administration
25 County Center Drive, Suite 200, Oroville, CA 95965
T: 530.552.3304 | F: 530.538.7120
From: lance dreiss <lancedreiss@att.net>
Sent: Monday, August 1, 2022 2:16 PM
To: Stephens, Brad J. <BStephens@buttecounty.net>; Ritter, Tami <TRitter@buttecounty.net>;
District Attorney <District_Attorney@buttecounty.net>; Waugh, Melanie
<mwaugh@buttecounty.net>; Kimmelshue, Tod <TKimmelshue@buttecounty.net>; Connelly, Bill
<BConnelly@buttecounty.net>; Lucero, Debra <DLucero@buttecounty.net>; Teeter, Doug
<DTeeter@buttecounty.net>; Clerk of the Board <clerkoftheboard@buttecounty.net>
Subject: Fwd: Public health emergency of international concern (PHEIC) FAKE
ATTENTION: This message originated from outside Butte County. Please exercise judgment before opening
..
attachments, clicking on links, or replying.
Sent from my iPad
Begin forwarded message:
From: lance dreiss <lancedreiss@att.net>
Date: August 1, 2022 at 2:14:31 PM PDT
To: Warren Dreiss <warrendreiss@gmail.com>
Subject: Public health emergency of international concern (PHEIC) FAKE
Board of Supervisors, Clerk of the Board, Public Record, DA Ramsey, Sheriff
Honea, County Counsel:
Please read the article from the NIH with this title: A randomized, placebo-
controlled trial of the safety and efficacy of tecovirimat for the treatment of
patients with monkeypox virus disease
*The WHO is corrupt
*Tedros Adhanon Ghebreyesus is a criminal
“creating virus in a lab”
Wuhan Institute of Virology
Monkey$pox
The fear-monger and deadly “vaccines” need to STOP!
https://cdn.who.int/media/docs/default-source/blue-print/day-2_veronique-
nussenblatt_vaccine-protocol_monkeypox-meeting_03june2022.pdf?
sfvrsn=bf68fc01_3
<day-2_veronique-nussenblatt_vaccine-protocol_monkeypox-
meeting_03june2022.pdf>
Every single person involved will be held responsible for their actions!
Sent from my iPad
, MHS
ScM
controlled trial of the safety and
-
PALM007
Bethesda, Maryland, USA
NIAID, National Institutes of Health
Monkeypox virus disease
Veronique Nussenblatt, MD,
A randomized, placebo
efficacy of Tecovirimat for the treatment of patients with
Disclosures
I have no financial interest or relationships to disclose.
) to initiate research collaboration.
MoH
History of PALM
government agreement was established between NIAID and
-
to
-
MoH
research response to the 2018 Ebola outbreak in Eastern Democratic Republic of Congo (DRC).A governmentthe DRC Ministry of Public Health (The outcome of this collaboration is a multilateral
clinical research program composed of NIAID, the National Institute of Biomedical Research (INRB)/
of
for
disease
tecovirimat
emergence
of
of
the
Africa
in
burden
efficacy
the
.
Saharan
greatest
-
resulted
Technologies
evaluated
sub
with
monkeypox)
in
has
pox,
SIGA
areas
trial
by
in
vaccination
(small
Orthopoxviruses
increasing
2022clinical
MPX
other
.
been
for
developed
to
EMA
Study rationale
smallpox
MPX
®),
have
controlled
246
-
human
routine
cases
(smallpox),
treatments
of
(ST
populations
of
2018
randomized
MPX
FDANo
--treatment
approved
HumanCessationsusceptibleNoTecovirimat
Primary and Secondary Objectives
To evaluate the virologic efficacy, as assessed by time to resolution of viremia, of tecovirimat relative to placebo for patients with monkeypox.with monkeypox as assessed by mortality,
clinical severity, and duration of symptoms.
Primary: To evaluate the clinical efficacy, as assessed by time to lesion resolution, of Tecovirimat (+SOC) compared placebo (+SOC) for patients with Monkeypox disease.Secondary:1)2)
To evaluate the clinical efficacy of tecovirimat (+SOC) versus placebo (+SOC) in patients 3) To evaluate the safety of tecovirimat relative to placebo for patients with monkeypox
OPXV antibodies on the course of disease
-
of HIV infection on monkeypox clinical outcomes
To evaluate the frequency and characteristics of persistent lesions.To develop a baseline disease severity metric for monkeypox.To assess the effectand treatment effect.To evaluate viral
persistence in skin lesions and in the oropharynx.To assess genomic variability in monkeypox virus isolated from participants based on geographic and clinical differences. To assess
if viral resistance develops due to selective pressure by treatment. To evaluate the impact of antiand the clinical efficacy of tecovirimat.To evaluate the trajectory of monkeypox IgM
and IgG during infection.To evaluate exposure history of confirmed monkeypox cases and to identify risk factors for monkeypox infection.
Exploratory Objectives
Clinical ViralSerologicEpidemiologic
-
.
criteria
laboratory
a
with
inclusion
meet
facilities
they
as
health
long
as
site
study
enrolled
the
be
to
will
admitted
infection
Study sites and subjects
patients
:
monkeypox
:
sitessubjects
Symptomaticconfirmed
StudyStudy
)
nateglinide
Current or planned use of a meglitinide (repaglinide, Planned use of midazolam while on study drug
Severe anemia, defined as HGB <7g/dLInability to safely swallow oral medicationsCurrent/planned use of other investigational drugPatients who, in the judgement of the investigator, will
be at significantly increased risk as a result of participation in the study
Exclusion Criteria:
the
not
.
by
culturally
active,
Eligibility criteria
or
one
procedures
.
provided
.
least
contraceptionstudy
at
all
present
if
:
consent
is
effective
representative,
follow
of
lesion
to
duration
representative
Criteria
useinformedlegal
to
illness
scabbed,
kg
3
AnyyetAgreeWillingnessWrittenpatient,acceptable
+ Monkeypox PCR from blood, oropharynx or skin lesion within 48 hours of screening.
Inclusion
58 days
treatment with
: lesion resolution
28 days
Primary endpoint(scabbing or desquamation stage) up to 28 days after randomization.Primary hypothesis:tecovirimat will increase the time to resolution of monkeypox lesions relative to
placebo.
then
+ SOC+ SOC
Placebo
Tecovirimat
.
until fully resolved
daily until fully resolved,
daily for 7 days then every other day until
PALM007
, 58
(yes/no)
: 1:1
daily until discharge
daily until discharge.
Study site
day 1, 14, 28
daily until negative x2 separated by 24 hours
Randomize
Strata:
every other day until discharge.
EvaluationsLesion counts in assessment region full body lesion assessment Clinical assessments MPX blood PCR MPX skin and oropharyngeal swabdischarge.Lab tests Blood for storage AE/SAE
monitoring
3kg1 active lesion
InclusionMPXV PCR+ Any ageExclusionSevere anemiaUse of a meglitinide /midazolamInability to swallow